CPAP Market Analysis, Size, Share & Growth Forecast 2026–2034

ResMed AirSense 11 Connected CPAP Transmitting Nightly Therapy Data From 15 Million Devices Has Created the Largest Remote Respiratory Care Monitoring Programme Enabling Adherence Support Without In-Person Follow-Up Visits.ResMed, Philips Respironics before recall, and Fisher and Paykel Healthcare supply the CPAP and auto-CPAP devices that the estimated 1 billion individuals with obstructive sleep apnoea worldwide require for the nightly positive pressure therapy that maintains upper airway patency and prevents the sleep fragmentation and hypoxaemia that apnoeic events cause. The auto-adjusting APAP devices that vary pressure delivery between a minimum and maximum setting based on real-time detection of respiratory events have improved patient adherence by reducing the time at unnecessarily high pressure while maintaining effective therapy, and the majority of new CPAP prescriptions are for APAP devices rather than fixed-pressure CPAP. The integrated Bluetooth connectivity and cloud data management in ResMed's AirSense series and Fisher and Paykel's SleepStyle enable the remote therapy monitoring that improves adherence management by allowing clinicians to review therapy data and contact patients with poor adherence before they abandon treatment.

Philips DreamStation Foam Degradation Recall Creating the Largest CPAP Safety Event in History Has Accelerated ResMed and Fisher and Paykel Share Gains and Elevated PAP Device Biocompatibility Material Testing Requirements.ResMed's myAir app, Philips DreamMapper, and Fisher and Paykel's SleepStyle app provide the patient engagement platforms that CPAP manufacturers use to display therapy data including AHI, mask leak, and usage hours in patient-friendly formats that motivate adherence through progress visualisation and personalised coaching. The heated humidification systems that warm and humidify the CPAP airflow to reduce nasal dryness and congestion that are common causes of patient discomfort have become standard features in the CPAP device market, and the auto-adjusting humidity systems from ResMed and Fisher and Paykel that adapt to ambient conditions eliminate the manual humidifier setting adjustments that earlier systems required. The mask design innovation from Resmed's AirFit P10 and F30i and Fisher and Paykel's Evora that has reduced contact area, improved seal, and lowered noise has addressed the mask discomfort and leak issues that have historically been the most common reasons for CPAP abandonment.

Home Sleep Testing Enabling OSA Diagnosis Without Overnight Laboratory Polysomnography Has Expanded the Diagnosed Patient Population by Providing Diagnostic Access That Laboratory Capacity Constraints and Geographic Barriers Previously Prevented.The AASM guidelines endorsing home sleep apnoea testing for uncomplicated OSA diagnosis have enabled the direct-to-consumer sleep apnoea evaluation services from companies including Lofta, Sleep.ai, and ResMed's sleep health platform that use FDA-cleared home sleep testing devices to diagnose OSA and initiate CPAP therapy without a clinic visit. The Medicare and insurance coverage of home sleep testing for OSA diagnosis and the FDA clearance of over-the-counter CPAP devices for mild to moderate OSA have created the regulatory framework that enables the consumer-direct sleep apnoea treatment market to operate within the medical device regulatory system. The AI-enhanced home sleep testing analysis using machine learning algorithms that analyse home sleep study signals with sensitivity and specificity approaching attended polysomnography has improved the diagnostic reliability of home testing, and the integration of wearable sensor data including pulse oximetry and accelerometry into the home sleep testing algorithm has extended the diagnostic information beyond the basic channel sets that early home sleep testing devices provided.

For related market intelligence, see the Obstructive Sleep Apnea Market.